Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme

BACKGROUND: The UK Risk Sharing Scheme (RSS) provided information on the effect of first-line multiple sclerosis (MS) disease-modifying treatments on long-term disability. OBJECTIVE: The aim is to provide results specific to glatiramer acetate (GA; Copaxone®) from the final 10-year analysis of the R...

Descripción completa

Detalles Bibliográficos
Autores principales: Giovannoni, G, Brex, PA, Dhiraj, D, Fullarton, J, Freddi, M, Rodgers-Gray, B, Schmierer, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896140/
https://www.ncbi.nlm.nih.gov/pubmed/31839981
http://dx.doi.org/10.1177/2055217319893103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896140/
https://www.ncbi.nlm.nih.gov/pubmed/31839981
http://dx.doi.org/10.1177/2055217319893103

Ejemplares similares